Haleos Labs Limited vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Haleos Labs Limited is ₹ 1511 as of 04 May 10:49 . The P/E Ratio of Haleos Labs Limited changed from 8.3 on March 2022 to 11 on March 2021 . This represents a CAGR of 5.79% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Haleos Labs Limited changed from ₹ 210.12 crore on March 2022 to ₹ 149.61 crore on March 2021 . This represents a CAGR of -6.57% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Haleos Labs Limited for the Dec '25 is ₹ 94.97 crore as compare to the Sep '25 revenue of ₹ 81.79 crore. This represent the growth of 16.11% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Haleos Labs Limited for the Dec '25 is ₹ 14.23 crore as compare to the Sep '25 ebitda of ₹ 13.99 crore. This represent the growth of 1.72% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 6.65 crore over 7 quarters. This represents a CAGR of -3.67% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Haleos Labs Limited and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Haleos Labs Limited or Syncom Formulations (India) Ltd?

Market cap of Haleos Labs Limited is 445 Cr while Market cap of Syncom Formulations (India) Ltd is 1,290 Cr

What are the key factors driving the stock performance of Haleos Labs Limited and Syncom Formulations (India) Ltd?

The stock performance of Haleos Labs Limited and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Haleos Labs Limited and Syncom Formulations (India) Ltd?

As of May 4, 2026, the Haleos Labs Limited stock price is INR ₹1474.9. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.73.

How do dividend payouts of Haleos Labs Limited and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Haleos Labs Limited and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.